AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15985128
Drug: Bupivacaine wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine wound infiltration 0.5%; 10 mL, followed by continuous infusion: 10 mg/24 H
Trial: 12660513
Drug: Tac triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tac triple therapy (n=185)
Trial: 10624454
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (440 IU) and Calcium (500 mg, 1250 mg calcium carbonate, Novartis) twice daily
Trial: 2172501
Drug: 2',3'-dideoxycytidine (ddC)
DrugBank: Zalcitabine (DB00943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2',3'-dideoxycytidine (ddC) at 0.015, 0.02, 0.03, and 0.04 mg/kg, given orally every 6 hours for 8 weeks
Trial: 2172501
Drug: Alternating schedule
RxNorm normalized name: HERBS/ALTERNATIVE THERAPIES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating schedule of ddC for 1 week followed by AZT (180 mg/m2 every 6 hours) for 3 weeks
Trial: 371371
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate aerosol, 50 mcg into each nostril four times a day
Trial: 371371
Drug: Placebo aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo aerosol therapy
Trial: 21244240
Drug: Synbiotic product
RxNorm normalized name: Synotic Otic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic product (3 tablets per day, 2.4 × 10^9 colony-forming units/day)
Trial: 19591795
Drug: AMA1 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMA1 vaccine
Trial: 17001106
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at 0.012 mg/kg/day for 24 weeks, followed by individualized dosing for another 24 weeks.
Trial: 10699140
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 12 mg/L of iron
Trial: 10699140
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 0.9 mg/L of iron
Trial: 8268277
Drug: Other hepatotoxic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other hepatotoxic drugs
Trial: 8268277
Drug: Concomitant exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant exposure to NSAIDs and other hepatotoxic drugs
Trial: 3979013
Drug: Deactivation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deactivation of cardiopulmonary receptors
Trial: 3979013
Drug: Stimulation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation of cardiopulmonary receptors
Trial: 29703007
Drug: 3 L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 L PEG alone
Trial: 29703007
Drug: 2 L PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 L PEG plus 30 mL castor oil
Trial: 29703007
Drug: 1 L PEG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L PEG, 30 mL castor oil and 5 g ascorbic acid
Trial: 9551706
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg t.i.d. pre- and co-treatment with cerivastatin 300 microg
Trial: 3046554
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of fluphenazine decanoate biweekly
Trial: 3046554
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of fluphenazine decanoate biweekly
Trial: 3046554
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of fluphenazine
Trial: 18079068
Drug: Disulfiram-Naltrexone combination
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram-Naltrexone combination
Trial: 12743557
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg per day for 16 weeks
Trial: 10560780
Drug: Men currently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men currently using illicit drugs
Trial: 10560780
Drug: Men currently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men currently taking HBP medication
Trial: 26173911
Drug: Inpatient prostaglandin
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient prostaglandin gel (IPG)
Trial: 21945130
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system (BTDS) 10 or 20 mcg/hour
Trial: 17061223
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (lidocaine 4%)
Trial: 11035828
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (behavior therapy)
Trial: 6498565
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 1.5 mg X kg‐1
Trial: 6498565
Drug: Ten per
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten per cent lidocaine nasal spray (30 mg in each nostril)
Trial: 6498565
Drug: 0.25 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 per cent phenylephrine nasal spray (0.2 mg in each nostril) (Group C)
Trial: 31987122
Drug: 10 capsules/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 capsules/day for four weeks
Trial: 31987122
Drug: 400 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL/day of a nutritional drink with the same dose of n‐3 LC PUFA
Trial: 24344215
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - standard treatment
Trial: 20695288
Drug: 20% picaridin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% picaridin spray
Trial: 20695288
Drug: 20% IR3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% IR3535 spray
Trial: 20695288
Drug: 20% picaridin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% picaridin lotion
Trial: 20695288
Drug: 10% IR3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% IR3535 lotion
Trial: 20695288
Drug: 33% DEET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% DEET cream
Trial: 9148172
Drug: Foreign levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Foreign levodopa preparation combined with carbidopa (25/250)
Trial: 9148172
Drug: Polish levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Polish levodopa preparation combined with carbidopa (25/250)
Trial: 1921737
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17 beta‐oestradiol (E2)
Trial: 1921737
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg Org OD 14
Trial: 6619028
Drug: Intravenous azlocillin
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous azlocillin at 6 g/day in three divided doses
Trial: 6619028
Drug: Intravenous ticarcillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ticarcillin at 8 g/day in four divided doses
Trial: 17667476
Drug: Risperidone (0.5-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5-6.0 mg/day)
Trial: 17667476
Drug: Molindone (10-140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molindone (10-140 mg/day)
Trial: 11258785
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) 4.5 g i.v. every 6 hours
Trial: 11258785
Drug: Clindamycin (Cl)
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin (Cl) 900 mg plus aztreonam (Az) 2 g i.v. every 8 hours
Trial: 3555943
Drug: Ibopamine 300
RxNorm normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 300 mg
Trial: 3555943
Drug: Metoclopramide (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (dopamine antagonist)
Trial: 3555943
Drug: Phentolamine (alpha-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (alpha-receptor antagonist) and Propranolol (beta-receptor antagonist)
Trial: 31009707
Drug: Xiang-Sha-Liu-Jun-Zi tang
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) 3.0 g three times daily for 28 days
Trial: 20082244
Drug: Pulian Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulian Ointment (NPLO)
Trial: 7954250
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (60 mg/m2 on Days 1-3 for the first course; 60 mg/m2 on Days 1-4 for the second course; 60 mg/m2 on Days 1-5 for the third course, recycled every 3 weeks)
Trial: 7954250
Drug: Intravenous vinblastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinblastine (3 mg/m2 weekly for 3 weeks, then 6 mg/m2 every 3 weeks)
Trial: 27965864
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for depersonalisation, delivered over six sessions within a maximum of 10 weeks.
Trial: 26380438
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment group (needling at Zusanli, Yanglingquan, Neiguan, Guanyuan, once per day for 6 days)
Trial: 26380438
Drug: Thymosin alpha1
RxNorm normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha1 group (subdermal injection of thymosin alpha1 1.6 mg, once per day for 6 days)
Trial: 26380438
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment according to Surviving Sepsis Campaign guidelines)
Trial: 23782493
Drug: Salient piece
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salient piece of candy prior to every infusion during three chemotherapy cycles
Trial: 23782493
Drug: Flavorless placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavorless placebo tablets
Trial: 19455176
Drug: Nutrient-enriched drink
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient-enriched drink (twice a day for 24 weeks)
Trial: 19455176
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (twice a day for 24 weeks)
Trial: 16495423
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%) applied to 'IV likely' patients
Trial: 2764526
Drug: Amoxicillin with
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin with probenecid
Trial: 800381
Drug: Fenbufen (600-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen (600-800 mg/day)
Trial: 800381
Drug: Fenbufen twice
RxNorm normalized name: fenbufen
DrugBank: Fenbufen (DB08981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen twice a day
Trial: 800381
Drug: Fenbufen (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen (both dosing regimens)
Trial: 25098377
Drug: Intensive vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vitamin D therapy (alfacalcidiol 0.25 mcg orally with each dialysis session + ergocalciferol 50,000 IU orally once per week)
Trial: 25098377
Drug: Standard vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vitamin D therapy (alfacalcidiol 0.25 mcg orally + placebo each dialysis session)
Trial: 25098377
Drug: Intensive vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vitamin D therapy
Trial: 25098377
Drug: Standard vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vitamin D therapy
Trial: 22743176
Drug: PPC heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPC heparin
Trial: 15784148
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment (n-propanol, 60% v/v)
Trial: 12461496
Drug: Pediatricians' personal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatricians' personal treatment preferences
Trial: 8603262
Drug: Dietary fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fish oil (MaxEPA 18 g/day) for 10 weeks
Trial: 1759538
Drug: Interferon 5
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 5 x 10(6) units thrice weekly for 4 months
Trial: 1759538
Drug: Interferon 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 0.25 x 10(6) U thrice weekly for 6 months (low dose)
Trial: 1759538
Drug: Interferon 3
RxNorm normalized name: interferon beta-1b 0.3 MG [Betaseron]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 3 x 10(6) U thrice weekly for 6 months (high dose)
Trial: 7044649
Drug: Clonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.2 mg single dose)
Trial: 7044649
Drug: Clonidine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.1 mg repeated doses bid)
Trial: 7044649
Drug: Clonidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (1 week treatment)
Trial: 7044649
Drug: Clonidine (S
RxNorm normalized name: Clonidine (substance)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (S and R doses) during dynamic physical activity (DPA)
Trial: 7044649
Drug: Clonidine (S
RxNorm normalized name: Clonidine (substance)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (S and R doses) during DPA
Trial: 25798575
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of statin therapy
Trial: 25798575
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of statin therapy
Trial: 22506302
Drug: Rockumentary music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rockumentary music therapy intervention
Trial: 27487408
Drug: Recreational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational music therapy
Trial: 22506302
Drug: Rockumentary music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rockumentary music therapy
Trial: 22506302
Drug: Verbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal therapy
Trial: 19150064
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg per day (A80)
Trial: 19150064
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg + Ezetimibe 10 mg per day (A10E10)
Trial: 7869212
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.65 ± 0.07 IU.kg‐1.wk‐1) and gonadotropin-releasing hormone analogs (66 ± 9 micrograms.kg‐1 every 28 days)
Trial: 7869212
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone administered alone after interruption of gonadotropin-releasing hormone analogs
Trial: 2531718
Drug: Alpha-hANP administration
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-hANP administration
Trial: 3086
Drug: Complete placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete placebo (orally and by vaccine)
Trial: 31628558
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser therapy (1500 J total energy, thrice/week for four weeks)
Trial: 31628558
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser therapy plus physical exercise program
Trial: 22821223
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance with mandibular advancement (active group)
Trial: 22821223
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance without advancement (control group)
Trial: 16949482
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg clopidogrel loading dose
Trial: 16949482
Drug: All clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All clopidogrel doses
Trial: 12940611
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg following dialysis (Phase I)
Trial: 12940611
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg during the last hour of hemodialysis (Phase II)
Trial: 12940611
Drug: Vancomycin 30
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 30 mg/kg during the last 2 hours of hemodialysis (Phase III)
Trial: 10852529
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (875/125 mg) administered orally 2 to 4 hours before surgery
Trial: 10852529
Drug: Amoxicillin alone
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin alone (implied as a comparison)
Trial: 9488196
Drug: Amlodipine (Norvasc),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (Norvasc), a third generation calcium channel blocker (CCB)
Trial: 8450247
Drug: 3 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 MIU of systemic recombinant interferon-alpha 2a given three times weekly for 4 weeks after CO2 laser ablation
Trial: 3698458
Drug: Diazepam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.2 mg/kg for 15 days followed by 0.3 mg/kg for 7 days)
Trial: 3698458
Drug: Oxazepam (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (0.8 mg/kg for 15 days followed by 1.2 mg/kg for 7 days)
Trial: 29481695
Drug: Middle ear
RxNorm normalized name: middle ear inflation device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle ear implants (MEIs)
Trial: 22273743
Drug: One-step self-etch
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (N'Durance, Septodont: N'D)
Trial: 22273743
Drug: One-step self-etch
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (Kalore, GC: Ka)
Trial: 22273743
Drug: One-step self-etch
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step self-etch adhesive (G-Bond, GC) with conventional composite (Z100, 3M ESPE)
Trial: 16301878
Drug: Bifrontal ECT
RxNorm normalized name: Bos taurus frontal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifrontal ECT (moderate dose, 50% above seizure threshold; n = 15)
Trial: 16301878
Drug: Bitemporal ECT
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitemporal ECT (low dose, just above seizure threshold; n = 15)
Trial: 16301878
Drug: Right unilateral
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right unilateral ECT (high dose, 400% above seizure threshold; n = 15)
Trial: 12173784
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg (loading dose)
Trial: 25633200
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied once every other day
Trial: 25633200
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate eye drops applied thrice daily
Trial: 18637604
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 mcg.kg(‐1)
Trial: 16767526
Drug: Teriparatide (20-mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20-mug subcutaneous, once daily)
Trial: 16767526
Drug: Antiresorptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive treatment (control group)